General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

News

  • Juergen Brokatzky-Geiger
    28-Oct-2013
    Juergen Brokatzky-Geiger appointed Global Head of Corporate Responsibility for Novartis

    In the context of increasing importance of corporate responsibility both for Novartis and for our stakeholders, we have decided to reinforce our efforts by establishing a new, full-time position that will integrate the Corporate Responsibility activities across the company. Juergen Brokatzky-Geiger, currently Global Head of Human Resources, will become Global Head of Corporate Responsibility effective February 26, 2014. In this role he will replace George Gunn, who has led our CR efforts since 2011, while leading our Animal Health Division at the same time.

    Learn more about leadership at Novartis

    Read biography

  • 02-Oct-2013
    Interrupting the transmission of leprosy

    The incidence of leprosy, an infectious disease that causes lumps and skin sores, has decreased by roughly 95%, but 233,000 new cases were reported in 2012.

    Read the article

  • 13-Sep-2013
    Africa struggles to fill its health worker shortage

    More than 1.5 million healthcare workers, including nurses and birthing attendants, are needed in Africa. The continent has 24% of the world’s disease burden.

    Read the article

  • 13-Sep-2013
    Making headway against malaria in Africa

    Malaria programs in sub-Saharan Africa are making progress by using insecticide-treated nets, diagnostic testing and Artemisinin-based Combination Therapy.

    Read the article

The information in the feature stories on these pages was factually accurate on the date of publication. These feature stories remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.